Literature DB >> 34879288

Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor Study Report.

Aman Wadhwa1, Yanjun Chen2, Lindsey Hageman2, Elizabeth Schlichting2, Erin Funk2, Jessica Hicks2, Nora Balas2, Arianna Siler2, Jessica Wu2, Liton Francisco2, Anna Holmqvist3, Ashish Gupta4, Troy Lund4, Paul J Orchard4, Saro Armenian5, Mukta Arora6, Smita Bhatia7.   

Abstract

Survival after blood or marrow transplantation (BMT) for inborn errors of metabolism (IEM) is excellent; however, the burden of morbidity in long-term survivors of BMT for IEM remains understudied. This study examined the risk of chronic health conditions (CHC) in ≥2-year survivors of allogeneic BMT for IEM performed between 1974 and 2014 using the BMT Survivor Study. In this retrospective cohort study, participants (or their parents; n = 154) reported demographic data and CHCs (graded using Common Terminology Criteria for Adverse Events version 5), and transplantation characteristics were obtained from institutional databases. Unaffected siblings (n = 494) served as a comparison group. Logistic regression was used to estimated the odds of severe/life-threatening CHCs compared with siblings. Cox proportional hazards regression was used to estimate factors associated with severe/life-threatening/fatal CHCs in survivors of BMT for IEM. Survivors of allogeneic BMT for IEM (leukodystrophies, 43.5%; mucopolysaccharidoses, 41.0%) were at 12.5-fold higher odds of severe/life-threatening CHCs (95% confidence interval [CI], 5.4 to 28.9) compared with their siblings. The mean 10-year post-BMT cumulative incidence of grade 3-5 CHCs was 47.5 ± 4.0%. Reduced-intensity conditioning (RIC) was associated with a 2.7-fold higher risk (95% CI, 1.2 to 6.2; P = .02) of any grade 3-5 CHC, a 6.7-fold higher risk of grade 3-5 cardiopulmonary conditions (95% CI, 1.3 to 35.4), and a 3.0-fold higher risk of severe hearing/vision deficits (95% CI, 1.4 to 6.6). Older (age >26 years) BMT survivors were significantly less likely to graduate from college (odds ratio [OR], 0.3; 95% CI, 0.1 to 0.7) or marry (OR, 0.01; 95% CI, 0.004 to 0.07) compared with their siblings. Survivors of BMT for IEM carry a significant burden of morbidities, which affects their ability to attain adult milestones. Efforts to reduce chronic health conditions in this population are needed.
Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Blood or marrow transplantation; Chronic health conditions; Inborn errors of metabolism; Morbidity

Mesh:

Year:  2021        PMID: 34879288      PMCID: PMC8923990          DOI: 10.1016/j.jtct.2021.11.023

Source DB:  PubMed          Journal:  Transplant Cell Ther        ISSN: 2666-6367


  19 in total

1.  Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Juvenile Metachromatic Leukodystrophy Compared With Nontransplanted Control Patients.

Authors:  Samuel Groeschel; Jörn-Sven Kühl; Annette E Bley; Christiane Kehrer; Bernhard Weschke; Michaela Döring; Judith Böhringer; Johanna Schrum; René Santer; Alfried Kohlschütter; Ingeborg Krägeloh-Mann; Ingo Müller
Journal:  JAMA Neurol       Date:  2016-09-01       Impact factor: 18.302

2.  Validation of self-reported complications by bone marrow transplantation survivors.

Authors:  A D Louie; L L Robison; M Bogue; S Hyde; S J Forman; S Bhatia
Journal:  Bone Marrow Transplant       Date:  2000-06       Impact factor: 5.483

3.  Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy.

Authors:  E Shapiro; W Krivit; L Lockman; I Jambaqué; C Peters; M Cowan; R Harris; S Blanche; P Bordigoni; D Loes; R Ziegler; M Crittenden; D Ris; B Berg; C Cox; H Moser; A Fischer; P Aubourg
Journal:  Lancet       Date:  2000-08-26       Impact factor: 79.321

4.  Enzyme-replacement therapy in mucopolysaccharidosis I.

Authors:  E D Kakkis; J Muenzer; G E Tiller; L Waber; J Belmont; M Passage; B Izykowski; J Phillips; R Doroshow; I Walot; R Hoft; E F Neufeld
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

5.  Long-term functional outcomes of children with hurler syndrome treated with unrelated umbilical cord blood transplantation.

Authors:  Hannah Y Coletti; Mieke Aldenhoven; Karina Yelin; Michele D Poe; Joanne Kurtzberg; Maria L Escolar
Journal:  JIMD Rep       Date:  2015-01-23

6.  Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies.

Authors:  Brigitte T A van den Broek; Kristin Page; Annalisa Paviglianiti; Janna Hol; Heather Allewelt; Fernanda Volt; Gerard Michel; Miguel Angel Diaz; Victoria Bordon; Tracey O'Brien; Peter J Shaw; Chantal Kenzey; Amal Al-Seraihy; Peter M van Hasselt; Andrew R Gennery; Eliane Gluckman; Vanderson Rocha; Annalisa Ruggeri; Joanne Kurtzberg; Jaap Jan Boelens
Journal:  Blood Adv       Date:  2018-01-04

7.  Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT).

Authors:  N Guffon; M Pettazzoni; N Pangaud; C Garin; G Lina-Granade; C Plault; C Mottolese; R Froissart; A Fouilhoux
Journal:  Orphanet J Rare Dis       Date:  2021-01-31       Impact factor: 4.123

8.  Late Mortality after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2).

Authors:  Aman Wadhwa; Yanjun Chen; Anna Holmqvist; Jessica Wu; Emily Ness; Mariel Parman; Michelle Kung; Lindsey Hageman; Liton Francisco; Elizabeth Braunlin; Weston Miller; Troy Lund; Saro Armenian; Mukta Arora; Paul Orchard; Smita Bhatia
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-04       Impact factor: 5.742

9.  Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases.

Authors:  Justine M Kahn; Ruta Brazauskas; Heather R Tecca; Stephanie Bo-Subait; David Buchbinder; Minoo Battiwala; Mary E D Flowers; Bipin N Savani; Rachel Phelan; Larisa Broglie; Allistair A Abraham; Amy K Keating; Andrew Daly; Baldeep Wirk; Biju George; Blanche P Alter; Celalettin Ustun; Cesar O Freytes; Amer M Beitinjaneh; Christine Duncan; Edward Copelan; Gerhard C Hildebrandt; Hemant S Murthy; Hillard M Lazarus; Jeffery J Auletta; Kasiani C Myers; Kirsten M Williams; Kristin M Page; Lynda M Vrooman; Maxim Norkin; Michael Byrne; Miguel Angel Diaz; Naynesh Kamani; Neel S Bhatt; Andrew Rezvani; Nosha Farhadfar; Parinda A Mehta; Peiman Hematti; Peter J Shaw; Rammurti T Kamble; Raquel Schears; Richard F Olsson; Robert J Hayashi; Robert Peter Gale; Samantha J Mayo; Saurabh Chhabra; Seth J Rotz; Sherif M Badawy; Siddhartha Ganguly; Steven Pavletic; Taiga Nishihori; Tim Prestidge; Vaibhav Agrawal; William J Hogan; Yoshihiro Inamoto; Bronwen E Shaw; Prakash Satwani
Journal:  Blood Adv       Date:  2020-05-12

10.  Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure.

Authors:  J J Boelens; R F Wynn; A O'Meara; P Veys; Y Bertrand; G Souillet; J E Wraith; A Fischer; M Cavazzana-Calvo; K W Sykora; P Sedlacek; A Rovelli; C S P M Uiterwaal; N Wulffraat
Journal:  Bone Marrow Transplant       Date:  2007-05-28       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.